Furthermore, overexpression of the EGR1 gene was also identified to be upregulated in ibrutinib-resistant MCL cells associated with metabolic reprogramming and OXPHOS pathway deregulation in MCL, thus providing another strategy to target BTKi-resistant cells. The gene discussed is IBTK; the disease is mantle cell lymphoma.